Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jul 5, 2011

Molecular Devices Takes Over Genetix’ Drug Discovery Unit

  • Genetix' drug discovery division has joined forces with Molecular Devices. The deal grows Molecular Devices beyond a technology supply company for research, biotechnology, and pharmaceutical companies.

    Founded in 1991, Genetix offers cell selection and cell imaging instrumentation and related products to basic and applied research scientists. The company’s key products are ClonePix™ and QPix™.

    ClonePix is an automated mammalian cell selection platform that has been designed to expedite the identification and selection of cells that produce biotherapeutic candidates. QPix colony pickers are reportedly used worldwide in over 600 installations. In addition, the CloneSelect™ Imager and CellReporter from Genetix will extend Molecular Devices' imaging portfolio.

    Molecular Devices offers a variety of detection technologies that meet all throughput needs from dedicated, single-readout devices to multireadout systems. The firm’s analytical products, which are for research use only, are used in basic research and discovery. The company’s headquarters are in Silicon Valley, and it has offices around the globe.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »